112 related articles for article (PubMed ID: 22964933)
21. Young investigator challenge: The utility of GATA3 immunohistochemistry in the evaluation of metastatic breast carcinomas in malignant effusions.
Lew M; Pang JC; Jing X; Fields KL; Roh MH
Cancer Cytopathol; 2015 Oct; 123(10):576-81. PubMed ID: 26465236
[TBL] [Abstract][Full Text] [Related]
22. Prognostic factors in patients with malignant pleural effusion: Is it possible to predict mortality in patients with good performance status?
Abrao FC; Peixoto RD; de Abreu IR; Janini MC; Viana GG; de Oliveira MC; Younes RN
J Surg Oncol; 2016 Apr; 113(5):570-4. PubMed ID: 26751412
[TBL] [Abstract][Full Text] [Related]
23. Diagnostic and prognostic values of endothelial-cell-specific molecule-1 with malignant pleural effusions in patients with non-small cell lung cancer.
Lu GJ; Shao CJ; Zhang Y; Wei YY; Xie WP; Kong H
Oncotarget; 2017 Jul; 8(30):49217-49223. PubMed ID: 28514746
[TBL] [Abstract][Full Text] [Related]
24. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
25. Correlation between DNA content, expression of Ki-67 antigen of tumor cells and immunophenotype of lymphocytes from malignant pleural effusions.
Sikora J; Dworacki G; Trybus M; Batura-Gabryel H; Zeromski J
Tumour Biol; 1998; 19(3):196-204. PubMed ID: 9591046
[TBL] [Abstract][Full Text] [Related]
26. HER2/HER3-positive metastatic salivary duct carcinoma in the pleural effusion: A case report.
Murata K; Kawahara A; Ono T; Takase Y; Abe H; Naito Y; Akiba J
Diagn Cytopathol; 2018 May; 46(5):429-433. PubMed ID: 29205961
[TBL] [Abstract][Full Text] [Related]
27. [Intrapleural administration with OK-432 and cultured autologous pleural effusion lymphocytes for breast cancer patients with malignant pleural effusions: analysis of 84 patients over a 14-year period].
Kan N
Gan To Kagaku Ryoho; 1999 Oct; 26(12):1796-800. PubMed ID: 10560397
[TBL] [Abstract][Full Text] [Related]
28. Prognostic value of cytosolic p53 protein in breast cancer.
Montero S; Guzmán C; Vargas C; Ballestín C; Cortés-Funes H; Colomer R
Tumour Biol; 2001; 22(5):337-44. PubMed ID: 11553865
[TBL] [Abstract][Full Text] [Related]
29. Prognostic significance of pleural fluid data in patients with malignant effusion.
Bielsa S; Salud A; Martínez M; Esquerda A; Martín A; Rodríguez-Panadero F; Porcel JM
Eur J Intern Med; 2008 Jul; 19(5):334-9. PubMed ID: 18549935
[TBL] [Abstract][Full Text] [Related]
30. [Differential prognosis of patients with breast cancer with pleuritis carcinomatosa and with pulmonary lymphangiosis carcinomatosa].
Baur M; Schlappack O; Jakesz R; Dittrich C
Wien Klin Wochenschr; 1992; 104(23):714-6. PubMed ID: 1475980
[TBL] [Abstract][Full Text] [Related]
31. Concurrent overexpression of p53 and c-erbB-2 correlates with accelerated cycling and concomitant poor prognosis in node-negative breast cancer.
Rudolph P; Alm P; Olsson H; Heidebrecht HJ; Fernö M; Baldetorp B; Parwaresch R
Hum Pathol; 2001 Mar; 32(3):311-9. PubMed ID: 11274641
[TBL] [Abstract][Full Text] [Related]
32. Immunophenotypic analysis of inflammatory breast cancers: identification of an 'inflammatory signature'.
Charafe-Jauffret E; Tarpin C; Bardou VJ; Bertucci F; Ginestier C; Braud AC; Puig B; Geneix J; Hassoun J; Birnbaum D; Jacquemier J; Viens P
J Pathol; 2004 Mar; 202(3):265-73. PubMed ID: 14991891
[TBL] [Abstract][Full Text] [Related]
33. [Clinical significance of MDR gene expression in malignant pleural effusion and ascites and solid tumors].
Feng Y; Hao X; Mao H
Zhonghua Yi Xue Za Zhi; 2001 Dec; 81(24):1484-7. PubMed ID: 16200770
[TBL] [Abstract][Full Text] [Related]
34. Diagnostic value of soluble receptor-binding cancer antigen expressed on SiSo cells and carcinoembryonic antigen in differentiating malignant from benign pleural effusion.
Dong J; Sun G; Zhu H
Tumour Biol; 2016 Mar; 37(3):3257-64. PubMed ID: 26438059
[TBL] [Abstract][Full Text] [Related]
35. p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer.
Clahsen PC; van de Velde CJ; Duval C; Pallud C; Mandard AM; Delobelle-Deroide A; van den Broek L; Sahmoud TM; van de Vijver MJ
J Clin Oncol; 1998 Feb; 16(2):470-9. PubMed ID: 9469330
[TBL] [Abstract][Full Text] [Related]
36. Prognostic value of soluble H7-B4 in pleural effusion associated with lung cancer.
Xu CH; Cao L; Zhang XW; Yan J; Yu LK
Tumour Biol; 2015 Jun; 36(6):4397-403. PubMed ID: 25636447
[TBL] [Abstract][Full Text] [Related]
37. Increased survivin mRNA in malignant pleural effusion is significantly correlated with survival.
Lan CC; Wu YK; Lee CH; Huang YC; Huang CY; Tsai YH; Huang SF; Tsao TC
Jpn J Clin Oncol; 2010 Mar; 40(3):234-40. PubMed ID: 19933689
[TBL] [Abstract][Full Text] [Related]
38. Thoracoscopic assessment of pleural tumor burden in patients with malignant pleural effusion: prognostic and therapeutic implications.
Sakr L; Maldonado F; Greillier L; Dutau H; Loundou A; Astoul P
J Thorac Oncol; 2011 Mar; 6(3):592-7. PubMed ID: 21258256
[TBL] [Abstract][Full Text] [Related]
39. Malignant pleural effusion from papillary thyroid carcinoma diagnosed by pleural effusion cytology: A case report.
Kosmas K; Tsonou A; Mitropoulou G; Salemi E; Kazi D; Theofanopoulou A
Diagn Cytopathol; 2018 Feb; 46(2):204-207. PubMed ID: 28960907
[TBL] [Abstract][Full Text] [Related]
40. Predicting survival in patients with recurrent symptomatic malignant pleural effusions: an assessment of the prognostic values of physiologic, morphologic, and quality of life measures of extent of disease.
Burrows CM; Mathews WC; Colt HG
Chest; 2000 Jan; 117(1):73-8. PubMed ID: 10631202
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
